原发性硬化性胆管炎及其转化之路。 - Suppr

Suppr

超能文献

Primary sclerosing cholangitis and the path to translation.

作者信息

Váncza Lóránd, Torok Natalie J

机构信息

Gastroenterology and Hepatology, Stanford University, Stanford, California, USA.

VA, Palo Alto, California, USA.

出版信息

J Clin Invest. 2023 Sep 1;133(17):e174218. doi: 10.1172/JCI174218.

DOI:10.1172/JCI174218

PMID:37655665

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10471165/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbac/10471165/b7977a60bf14/jci-133-174218-g161.jpg

相似文献

Primary sclerosing cholangitis and the path to translation.原发性硬化性胆管炎及其转化之路。

J Clin Invest. 2023 Sep 1;133(17):e174218. doi: 10.1172/JCI174218.

Sclerosing cholangitis.硬化性胆管炎

Curr Opin Gastroenterol. 2005 May;21(3):348-53. doi: 10.1097/01.mog.0000155359.43763.cc.

Sclerosing cholangitis.硬化性胆管炎

Curr Opin Gastroenterol. 2006 May;22(3):288-93. doi: 10.1097/01.mog.0000218966.78558.67.

Autoimmune Hepatitis, Sclerosing Cholangitis, and Autoimmune Sclerosing Cholangitis or Overlap Syndrome.自身免疫性肝炎、硬化性胆管炎和自身免疫性硬化性胆管炎或重叠综合征。

Clin Liver Dis. 2018 Nov;22(4):689-702. doi: 10.1016/j.cld.2018.06.005.

An update on primary sclerosing cholangitis.原发性硬化性胆管炎的最新进展。

Curr Opin Gastroenterol. 2008 May;24(3):377-83. doi: 10.1097/MOG.0b013e3282f9e239.

Secondary Sclerosing Cholangitis: a Review of Recent Literature.继发性硬化性胆管炎：近期文献综述

Curr Gastroenterol Rep. 2017 Sep;19(9):44. doi: 10.1007/s11894-017-0583-8.

[Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)].[原发性硬化性胆管炎的诊断与管理指南（2021年）]

Zhonghua Gan Zang Bing Za Zhi. 2022 Feb 20;30(2):169-189. doi: 10.3760/cma.j.cn112138-20211109-00786.

Primary sclerosing cholangitis.原发性硬化性胆管炎

Gastroenterol Nurs. 2007 Mar-Apr;30(2):102-5; quiz 105-7. doi: 10.1097/01.SGA.0000267929.62298.64.

Sclerosing cholangitis: pediatric perspective.硬化性胆管炎：儿科视角

Curr Gastroenterol Rep. 2010 Jun;12(3):195-202. doi: 10.1007/s11894-010-0104-5.

Medical and endoscopic treatment in primary sclerosing cholangitis.原发性硬化性胆管炎的医学及内镜治疗

Best Pract Res Clin Gastroenterol. 2001 Aug;15(4):657-66. doi: 10.1053/bega.2001.0211.

引用本文的文献

Mesenchymal stem cell-derived extracellular vesicles attenuate periductal fibrosis by inhibiting Th17 differentiation in human liver multilineage organoids and Mdr2 mice.间充质干细胞衍生的细胞外囊泡通过抑制人肝脏多谱系类器官和Mdr2小鼠中的Th17分化来减轻导管周围纤维化。

J Nanobiotechnology. 2025 Jul 28;23(1):546. doi: 10.1186/s12951-025-03617-2.

Regulatory T cell therapy in autoimmune liver disease and transplantation.自身免疫性肝病和移植中的调节性T细胞疗法。

JHEP Rep. 2025 Mar 12;7(8):101394. doi: 10.1016/j.jhepr.2025.101394. eCollection 2025 Aug.

24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T17 pathogenicity and transdifferentiation.24-去甲熊去氧胆酸通过靶向T17致病性和转分化改善肠道炎症。

Gut. 2025 Jun 6;74(7):1079-1093. doi: 10.1136/gutjnl-2024-333297.

The Association Between Primary Sclerosing Cholangitis and Microscopic Colitis: A Systematic Review.原发性硬化性胆管炎与显微镜下结肠炎之间的关联：一项系统评价

Cureus. 2024 Dec 12;16(12):e75587. doi: 10.7759/cureus.75587. eCollection 2024 Dec.

本文引用的文献

Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis.噬菌体治疗对病理性肺炎克雷伯菌的影响可改善原发性硬化性胆管炎的病程。

Nat Commun. 2023 Jun 5;14(1):3261. doi: 10.1038/s41467-023-39029-9.

Predicting cholangiocarcinoma in primary sclerosing cholangitis: using artificial intelligence, clinical and laboratory data.预测原发性硬化性胆管炎中的胆管癌：使用人工智能、临床和实验室数据。

BMC Gastroenterol. 2023 Apr 19;23(1):129. doi: 10.1186/s12876-023-02759-7.

PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.PRIMIS：一项关键性、随机、3 期研究的设计，评估非甾体法尼醇 X 受体激动剂西罗福西安在非肝硬化原发性硬化性胆管炎患者中的安全性和疗效。

BMC Gastroenterol. 2023 Mar 15;23(1):75. doi: 10.1186/s12876-023-02653-2.

Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis.多基因全基因组分析鉴定原发性硬化性胆管炎的新易感位点和候选药物。

Nat Commun. 2023 Feb 24;14(1):1069. doi: 10.1038/s41467-023-36678-8.

Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2 -/- mice.长期给予促胰液素受体拮抗剂可抑制Mdr2 -/-小鼠的胆管衰老和肝纤维化。

Hepatology. 2023 Jun 1;77(6):1849-1865. doi: 10.1097/HEP.0000000000000310. Epub 2023 Feb 20.

Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.在原发性硬化性胆管炎患者中，法尼醇 X 受体（FXR）激动剂 cilofexor 的 96 周开放标签扩展研究中的安全性和持续疗效。

Clin Gastroenterol Hepatol. 2023 Jun;21(6):1552-1560.e2. doi: 10.1016/j.cgh.2022.07.024. Epub 2022 Aug 4.

Mast cells selectively target large cholangiocytes during biliary injury via H2HR-mediated cAMP/pERK1/2 signaling.肥大细胞在胆汁淤积损伤过程中通过 H2HR 介导的 cAMP/ERK1/2 信号选择性靶向大胆管细胞。

Hepatol Commun. 2022 Oct;6(10):2715-2731. doi: 10.1002/hep4.2026. Epub 2022 Jul 7.

Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.保护性和侵袭性细菌亚群及其代谢产物可改变 PSC 小鼠模型的肝胆炎症和纤维化。

Gut. 2023 Apr;72(4):671-685. doi: 10.1136/gutjnl-2021-326500. Epub 2022 Jun 15.

Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis.难治性溃疡性结肠炎合并原发性硬化性胆管炎患者的自体调节性 T 细胞转移。

Gut. 2023 Jan;72(1):49-53. doi: 10.1136/gutjnl-2022-327075. Epub 2022 Apr 15.

Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling.肠道微生物群的耗竭通过法尼醇X受体（FXR）信号通路的丧失加剧胆汁淤积性肝损伤。

Nat Metab. 2021 Sep;3(9):1228-1241. doi: 10.1038/s42255-021-00452-1. Epub 2021 Sep 22.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验